Appointment of Paul Brennan as Non-Executive Director
March 16 2022 - 9:30AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian
biopharmaceutical company focused on developing and commercializing
oral immunotherapeutics for the prevention and treatment of gut
mediated pathogens, is pleased to announce the appointment of Paul
Brennan as an independent Non-Executive Director of the Company
with effect from today.
Mr Brennan has
extensive experience in the health system through his clinical
background and commercial exposure with various multinational
companies. Mr Brennan was Chief Executive Officer (CEO) of PolyNovo
Limited (ASX:PNV) for 7 years from 2015 to 2021 and took the
company from $30M to a high of $2B. Prior to this Mr Brennan was
Marketing Director Australia and New Zealand and Sales Director New
Zealand for Smith & Nephew Healthcare for 6 years.
Commenting on his
appointment, Paul Brennan said, “Immuron has unique intellectual
property that places it at the forefront of gut health. This
emerging field of medical advancement, coupled with Immuron’s
strength in clinical research, should deliver significant market
opportunity. I am looking forward to working closely with the
team.”
Dr. Roger Aston,
Non-Executive Chairman, said, “we are delighted with the
appointment of Paul to the Board as he brings a diverse background
including commercialisation of technology, company governance,
strategic planning and international marketing and more.”
This release has been authorised by the
directors of Immuron Limited.
COMPANY
CONTACT:
Dr Jerry Kanellos, Ph.D.Chief
Executive OfficerPh: +61 (0)3 9824 5254info@immuron.com
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jul 2023 to Jul 2024